The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Links

 

Gene Review

NAA10  -  N(alpha)-acetyltransferase 10, NatA...

Homo sapiens

Synonyms: ARD1, ARD1A, ARD1P, DXS707, MCOPS1, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of ARD1A

 

High impact information on ARD1A

  • Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation [6].
  • Therefore, it is suggested that hARD1 participates in proliferation of lung cancer cells via the activation of beta-catenin [1].
  • Arrest defective 1 (ARD1), an acetyltransferase, is essential for the yeast life cycle [1].
  • In addition to the HIF proline hydroxylases and asparagine hydroxylases, ARD1 is recently described as a HIF-1alpha acetylase that regulates its stability [2].
  • After surveying these lines for erythropoietin production and retroviral transfection efficiency, we chose to use HepG2 cells to study the function of ARD1 [2].
 

Biological context of ARD1A

 

Anatomical context of ARD1A

  • Here, we demonstrate that knockdown of NATH and/or hARD1 triggers apoptosis in human cell lines [8].
  • We also demonstrate that ARD1 is a stable, predominantly cytoplasmic protein expressed in a broad range of tissues, tumor cell lines, and endothelial cells [3].
  • RESULTS: In normal subjects, tendon stimulation elicited an excitatory phase (TE1), followed by a pronounced inhibitory phase (TI1) and a second excitatory phase (TE2) [9].
  • METHODS: Cancer cell lines from the lung (H460, H322), the esophagus (TE2, TE12), and the pleura (H290, H211) or primary normal cells were treated with gossypol+Apo2L/TRAIL combinations [10].
 

Associations of ARD1A with chemical compounds

  • In addition, hARD1 forms protofilaments under physiological conditions of pH and temperature, as judged by electron microscopy and staining with the dyes Congo red and thioflavin T [11].
  • In NB4 cells undergoing retinoic acid mediated differentiation, the level of endogenous hARD1 and NATH protein decreases while the level of hARD2 protein is stable [7].
  • Knockdown of hARD1 also sensitized cells to daunorubicin-induced apoptosis, potentially pointing at the NATH-hARD1 acetyltransferase complex as a novel target for chemotherapy [8].
  • In contrast, the growth of TE2/TK tumors was significantly inhibited by GCV and all the tumors disappeared [12].
  • DESIGN, SETTING AND METHODS: We analysed total estrogen (TE) and testosterone (TT) levels in women diagnosed with AD and controls of the Oxford Project To Investigate Memory and Ageing. Because estradiol (TE2) after the menopause is largely derived from estrone (TE1), we computed the ratio TE2/(TE1+TE2) and a total steroid index (TT+TE2+TE1) [13].
 

Analytical, diagnostic and therapeutic context of ARD1A

  • Structural characterization of native hARD1 using size exclusion chromatography, circular dichroism, and fluorescence spectroscopy shows the protein consists of a compact globular region comprising two thirds of the protein and a flexible unstructured C terminus [11].
  • A gene chip analysis of HepG2 cells transduced with virus expressing ARD1 short hairpin RNA under normoxia and hypoxia conditions or with virus overexpressing recombinant ARD1 confirmed that inhibition of ARD1 does not cause activation of HIF and downstream target genes [2].
  • Cells were transiently transfected with HIF-1alpha mutant and antisense arrest-defective 1 protein (ARD-1), and HIF-1alpha acetylation was assayed by immunoprecipitation [14].
  • In mouse xenograft models of T.Tn and TE2 cells, FK228 injection resulted in significant tumor regression as well as activated Prdx1 expression in tumor tissues [5].
  • EXPERIMENTAL DESIGN: TE-2 proteins were separated by two-dimensional PAGE, followed by Western blot analysis in which sera of patients with ESCC, healthy controls, and patients with other cancers were tested for primary antibodies [15].

References

  1. Human Arrest Defective 1 Acetylates and Activates {beta}-Catenin, Promoting Lung Cancer Cell Proliferation. Lim, J.H., Park, J.W., Chun, Y.S. Cancer Res. (2006) [Pubmed]
  2. Analysis of ARD1 function in hypoxia response using retroviral RNA interference. Fisher, T.S., Etages, S.D., Hayes, L., Crimin, K., Li, B. J. Biol. Chem. (2005) [Pubmed]
  3. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. Bilton, R., Mazure, N., Trottier, E., Hattab, M., Déry, M.A., Richard, D.E., Pouysségur, J., Brahimi-Horn, M.C. J. Biol. Chem. (2005) [Pubmed]
  4. Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Kimura, S., Kitadai, Y., Tanaka, S., Kuwai, T., Hihara, J., Yoshida, K., Toge, T., Chayama, K. Eur. J. Cancer (2004) [Pubmed]
  5. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Hoshino, I., Matsubara, H., Hanari, N., Mori, M., Nishimori, T., Yoneyama, Y., Akutsu, Y., Sakata, H., Matsushita, K., Seki, N., Ochiai, T. Clin. Cancer Res. (2005) [Pubmed]
  6. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Jeong, J.W., Bae, M.K., Ahn, M.Y., Kim, S.H., Sohn, T.K., Bae, M.H., Yoo, M.A., Song, E.J., Lee, K.J., Kim, K.W. Cell (2002) [Pubmed]
  7. Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase. Arnesen, T., Betts, M.J., Pendino, F., Liberles, D.A., Anderson, D., Caro, J., Kong, X., Varhaug, J.E., Lillehaug, J.R. BMC Biochem. (2006) [Pubmed]
  8. Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex. Arnesen, T., Gromyko, D., Pendino, F., Ryningen, A., Varhaug, J.E., Lillehaug, J.R. Oncogene (2006) [Pubmed]
  9. Impaired EMG inhibition elicited by tendon stimulation in dystonia. Lorenzano, C., Priori MD, A., Currà, A., Gilio, F., Manfredi, M., Berardelli, A. Neurology (2000) [Pubmed]
  10. Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. Yeow, W.S., Baras, A., Chua, A., Nguyen, D.M., Sehgal, S.S., Schrump, D.S., Nguyen, D.M. J. Thorac. Cardiovasc. Surg. (2006) [Pubmed]
  11. Characterization of the native and fibrillar conformation of the human Nalpha-acetyltransferase ARD1. Sánchez-Puig, N., Fersht, A.R. Protein Sci. (2006) [Pubmed]
  12. Differential efficacy of suicide gene therapy by herpes simplex virus-thymidine kinase gene reflects the status of p53 gene in human esophageal cancer cells. Matsubara, H., Kawamura, K., Sugaya, M., Koide, Y., Gunji, Y., Takenaga, K., Asano, T., Ochiai, T., Sakiyama, S., Tagawa, M. Anticancer Res. (1999) [Pubmed]
  13. The interaction of serum folate and estradiol levels in Alzheimer's disease. Hogervorst, E., Smith, A.D. Neuro Endocrinol. Lett. (2002) [Pubmed]
  14. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. Chang, C.C., Lin, M.T., Lin, B.R., Jeng, Y.M., Chen, S.T., Chu, C.Y., Chen, R.J., Chang, K.J., Yang, P.C., Kuo, M.L. J. Natl. Cancer Inst. (2006) [Pubmed]
  15. Proteomics-Based Approach Identifying Autoantibody against Peroxiredoxin VI as a Novel Serum Marker in Esophageal Squamous Cell Carcinoma. Fujita, Y., Nakanishi, T., Hiramatsu, M., Mabuchi, H., Miyamoto, Y., Miyamoto, A., Shimizu, A., Tanigawa, N. Clin. Cancer Res. (2006) [Pubmed]
 
WikiGenes - Universities